US and new launches (including Namenda, Propofol, Xeloda, Angiomax, Nexium, Copaxone) will sustain nearterm growth. What could surprise our FY17 estimates positivelyanddrivevaluegrowthfurtherisDRL's(guided)launchofthreeNDAsinearly...